Kashiv BioSciences Secures INR 648 Cr Financing to Expand Pipan Manufacturing Facility

The investment is set to drive the development of a state-of-the-art biologics production facility, positioning the site as one of India’s largest single-use commercial manufacturing units.

Kashiv BioSciences, a leading biopharmaceutical company, has secured INR 648 crore in financing from the Union Bank of India (UBI) to expand its manufacturing operations in Pipan, near Ahmedabad, Gujarat.

The investment is set to drive the development of a state-of-the-art biologics production facility, positioning the site as one of India’s largest single-use commercial manufacturing units.

The new facility will integrate advanced technologies to support large-scale production of high-quality biologics and specialty pharmaceuticals. Once fully operational, Kashiv anticipates an annual manufacturing capacity of up to 50,000 liters, a significant milestone for the company’s expansion plans.

“This funding marks a pivotal milestone in Kashiv’s journey to expand biomanufacturing capacity in India,” said Dr. Sandeep Athalye, Global CEO of Kashiv BioSciences. “The new facility in Pipan will accelerate innovation and access to high-quality biologics, supported by Union Bank of India and aligned with the Gujarat State Biotechnology Mission’s initiatives.”

The expansion aligns with India’s broader focus on advancing biopharmaceutical infrastructure. The Gujarat State Biotechnology Mission (GSBTM), a state government body, has actively promoted investment in biomanufacturing, supporting companies like Kashiv in establishing high-capacity, technology-driven facilities.

Kashiv BioSciences’ Pipan unit is designed to leverage single-use technologies, which offer enhanced flexibility, reduced contamination risk, and faster production cycles compared to traditional stainless-steel systems. These features make the facility suitable for both domestic and international markets, reinforcing India’s growing role in global biopharmaceutical production.

The Rs 648 crore financing from UBI will not only fund construction and technology deployment but also strengthen Kashiv’s capabilities in specialty pharmaceutical development. The company has highlighted that this infrastructure will support both research and large-scale manufacturing, enabling faster delivery of biologics to patients and partners worldwide.

Stay tuned for more such updates on Digital Health News